＜4374＞ Robopay 2422 +82

Continuing the upward trend. After the market closes on the 12th, the monthly revenue for November 2024 will be announced, which is being viewed as positive news. The monthly revenue for November showed a 22.6% increase year-on-year, amounting to 0.243 billion yen, confirming the ongoing upward trend in revenue. The monthly revenue from the invoice management robot also increased by 19.8% to 0.093 billion yen, while the main subscription pay service increased by 25.5% to 0.149 billion yen, reflecting solid growth.

＜4445＞ LivinT 2776 +116

Continuing to rise. It has been announced that a new AI (Artificial Intelligence) scoring feature has been developed and implemented to achieve high-accuracy matching for the DX platform 'Livin Match' that connects end-users and companies in the residential reuse sector, which is being viewed positively. The AI scoring function will utilize over 0.6 million accumulated data points stored in 'Livin Match' to build and refine learning models for analysis and forecasting. This scoring AI model is expected to not only improve matching accuracy but also be applied and incorporated into applications that will be developed in the future.

＜219A＞ Heart Seed 1941 +381

Temporarily reached the limit up. Following the trading session on the 12th, the financial results for the fiscal year ending October 2024 were announced, leading to a positive inflow of buying. Revenue increased by 153.4% year-on-year to 0.873 billion yen, while recurring losses shrank to a deficit of 0.818 billion yen (compared to a 1.456 billion yen deficit in the previous term). Regarding the financial estimates for the fiscal year ending October 2025, it is anticipated that revenue will be 2.394 billion yen (an increase of 174.0% from the previous term) based on achievable milestone revenue schedules, with recurring losses expected to further shrink to a deficit of 0.47 billion yen.

＜7097＞ Sakura Saku 1315 +300

Limit up. It has been announced that a new shareholder benefit program will be established. Shareholders listed or recorded in the shareholder registry with a holding of 2 units (200 shares) or more as of the end of January and July each year will receive a total of 20,000 yen worth of QUO cards (10,000 yen worth of QUO cards twice a year on each reference date). The company continues to invest in growth through M&A in the femcare and femtech business and plans to increase dividends for the fourth consecutive term. Although the recurring profit for the first quarter ending July 2025 announced on the same day was 0.025 billion yen, a decrease of 49.6% compared to the same period last year, buying is actively taking place.

<215A> Timee 1490 +300

The stock reached its upper limit. For the fiscal year ending in October 2024, revenue was 26.88 billion yen (up 66.5% year-on-year), and ordinary profit was 3.924 billion yen (up 103.9% year-on-year), showing significant growth in both revenue and profit. The number of registered workers exceeded 9.5 million, the number of registered client business locations exceeded 316,000, and the total amount of distribution (the total amount of wages and rewards paid to workers, etc.) was 90.779 billion yen (up 66.6% year-on-year). For the fiscal year ending in October 2025, revenue is expected to increase 28.0% to 32.8% year-on-year to between 34.394 billion and 35.7 billion yen, and ordinary income is expected to increase 51.4% to 69.5% year-on-year to between 5.943 billion and 6.653 billion yen.

<4579> Raqualia Pharmaceutical 413 -2

While the buying trend initially led, the prices have erased gains and are now in a sideways trend. After the close of trading on the 12th, it was announced that HK Innoen's partner, Carnot, has launched a new product in five Latin American countries regarding the acid secretion inhibitor tegoprazan, which was derived from HK Innoen. This news is seen as positive. The number of countries where tegoprazan products are sold has expanded to 15. Carnot is actively conducting marketing activities for 'Ki-CAB' within its territory, and in Mexico, where product launch was the quickest, it holds the third position in the market share of digestive ulcer agents, with further growth expected in the future.